AzTrials
AzTrials

Atrial FibrillationTRACK-AFNCT02641678

Follow-up of Kryptogenic Stroke Patients With Implantable vs. Non-invasive Devices to Detect Atrial Fibrillation.

An observational study of Atrial Fibrillation and Stroke, run by University Hospital Muenster.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Prospective mono-center diagnostic study determining potential discrepancies in identifying atrial fibrillation by intraindividually comparing different types of follow-up strategies: 1. How many stroke patients with atrial fibrillation are missed by standard stroke unit 24h- electrocardiography, and 2. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Atrial Fibrillation, Stroke
What is being tested?
Implantation of cardiac monitor
Type of treatment
Medical device
How many people
106 participants
Where
No sites listed yet
Study dates
Mar 2013to Jun 2015
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with stroke of unknown etiology

Who may be able to join

  • Patients years with acute ischemic stroke of unknown cause, monitored on a stroke unit undergoing routine diagnostic procedures (conventional 12-lead-ECG, 24h-ECG, echocardiography, cCT or cMRI, Transcranial Doppler and carotid duplex ultrasound, long-term blood pressure monitoring, standard laboratory investigations)

Who cannot join

  • Stroke with known etiology, Stroke caused by intracranial hemorrhage

About this study

Prospective mono-center diagnostic study determining potential discrepancies in identifying atrial fibrillation by intraindividually comparing different types of follow-up strategies:

  1. How many stroke patients with atrial fibrillation are missed by standard stroke unit 24h- electrocardiography, and
  2. what is the effectiveness of the extended invasive and non-invasive ECG analysis tools to detect atrial fibrillation in stroke patients?
Read the detailed description

Atrial fibrillation often is paroxysmal and asymptomatic and, therefore, often not detected. Because atrial fibrillation is the leading risk factor for ischemic stroke, and oral anticoagulation is very efficacious for both primary and secondary stroke prevention in atrial fibrillation patients, detection of atrial fibrillation is essential to prevent stroke and stroke-induced disability and death. The incidence of atrial fibrillation and paroxysmal atrial fibrillation is particularly high in stroke patients. Short duration monitoring identified new atrial fibrillation in only about 5% to 10% of stroke patients. Estimates of missed paroxysmal atrial fibrillation in stroke patients go up to 40 000 patients in Germany per year.

Due to the known poor sensitivity of a 24h-ECG, all patients with stroke of unknown cause will undergo the above mentioned non-invasive and invasive ECG monitoring. Based on the data of these extended ECG-analyses, the rate of missed AF in conventionally diagnosed stroke unit patients could be determined by comparison to the 24h-ECG results. Additionally, a cost-benefit equation of the different ECG analysis tools will be calculated by comparison of the respective detection rates and the known follow-up costs.

Inclusion criteria: Patients years with acute ischemic stroke of unknown cause, monitored on a stroke unit undergoing routine diagnostic procedures (conventional 12-lead-ECG, 24h-ECG, echocardiography, cranial computed tomography or cranial magnetic resonance tomography, Transcranial Doppler and carotid duplex ultrasound, long-term blood pressure monitoring, standard laboratory investigations) Exclusion criteria: Stroke with known etiology, Stroke caused by intracranial hemorrhage

Diagnosis-as-usual:

  • Standard 24h-ECG on stroke units according to existing guidelines

Investigational measure:

Non-invasive:

  • Online ECG analysis during the standardized stroke unit- monitoring
  • Ambulatory 7-day ECG monitoring

Invasive:

  • atrial fibrillation detection by a permanently implantable direct cardiac rhythm monitor device in a period of up to 6 month

Duration of measures per patient:

2 weeks hospitalization, ~1 month rehabilitation, then implantation of the ECG device, and 6 months follow-up: 7.5 months in total

Primary outcome:

To determine the prevalence of undiagnosed AF in stroke patients undergoing the diagnostic standard (24h-ECG)

Secondary outcome:

Effectivity and cost-effectiveness ratios of the different ECG analyis tools

Description of the outcome:

Based on the obtained data, the prevalence of undiagnosed atrial fibrillation in stroke patients whom atrial fibrillation is missed by the standard diagnostic procedure (24h-ECG) will be determined by different extensive non-invasive and invasive ECG monitoring tools.

Additionally, following values of the applied ECG analysis tools will be calculated and compared:

  • Sensitivity: (true positives) / (true positives + false negatives)
  • Specificity: (true negatives) / (true negatives + false positives)
  • Positive predicted value: (true positives) / (true positives + false positives)
  • Negative predicted value: (true negatives) / (true negatives + false negatives)

Safety:

The implantable direct cardiac rhythm monitor device is an established and widely used diagnostic procedure in patients with unexplained syncope.

Being tested
Implantation of cardiac monitor
Keywords
Atrial Fibrillation, stroke, implantable cardiac monitor, automated ECG analysis
Medical subject headings
Atrial Fibrillation, Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Implantation of cardiac monitorDevice

    In patients with kryptogenic stroke, a cardiac monitor was implanted to detect atrial fibrillation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To determine the prevalence of undiagnosed AF in stroke patients undergoing the diagnostic standard (24h-ECG)

    Based on the obtained data, the prevalence (in percent) of undiagnosed AF in stroke patients whom AF is missed by the standard diagnostic procedure (24h-ECG) will be determined by different extensive non-invasive and invasive ECG monitoring tools

    Measured: 7.5 months

Secondary outcomes (1)
  1. Diagnostic accuracy of the automated software based ECG analysis in comparison to the "gold-standard" the implanted cardiac monitor

    The Sensitivity (in percent), the Specificity (in percent), the positive predictive value (in percent) and the negative predictive value (in percent) will be calculated for the automated ECG software analysis in comparison to the "gold-standard" the implanted cardiac monitor

    Measured: 7.5 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Dec 2015 (estimated)
  2. Study startMar 2013
  3. Primary completionDec 2014
  4. Study completionJun 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
106 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02641678
Sponsor's protocol ID
TRACK-AF
Acronym
TRACK-AF
Status last verified
Jan 2016
First submitted
22 Dec 2015
Last updated
21 Jan 2016
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Bettin M, Dechering D, Kochhauser S, Bode N, Eckardt L, Frommeyer G, Reinke F. Extended ECG monitoring with an implantable loop recorder in patients with cryptogenic stroke: time schedule, reasons for explantation and incidental findings (results from the TRACK-AF trial). Clin Res Cardiol. 2019 Mar;108(3):309-314. doi: 10.1007/s00392-018-1358-4. Epub 2018 Aug 22.

    PubMed 30167809
  • Reinke F, Bettin M, Ross LS, Kochhauser S, Kleffner I, Ritter M, Minnerup J, Dechering D, Eckardt L, Dittrich R. Refinement of detecting atrial fibrillation in stroke patients: results from the TRACK-AF Study. Eur J Neurol. 2018 Apr;25(4):631-636. doi: 10.1111/ene.13538. Epub 2018 Feb 13.

    PubMed 29205690

Questions about this trial

What is this clinical trial studying?

An observational study of Atrial Fibrillation and Stroke, run by University Hospital Muenster.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Jan 2016. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To determine the prevalence of undiagnosed AF in stroke patients undergoing the diagnostic standard (24h-ECG) (time frame: 7.5 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02641678, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in